Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Assets Average data on file, last reported at $461.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 18.43% year-over-year to $461.3 million in Q1 2026; TTM through Mar 2026 was $461.3 million, a 18.43% increase from a year earlier, with the FY2025 full-year figure at $436.2 million, up 20.34% from the prior year.
• Assets Average for Q1 2026 stood at $461.3 million, down from $493.5 million in the prior quarter.
• Over the last five years, Assets Average for RYTM reached as high as $493.5 million in Q4 2025 and fell as low as $281.2 million in Q2 2022.
• Historically, Assets Average has averaged $365.1 million across 5 years, with a median of $364.1 million in 2023.
• Across the five-year window, Assets Average plunged 30.61% in 2022 and soared 31.72% in 2025, its largest moves.
• Year by year, Assets Average stood at $386.0 million in 2022, then dropped by 11.03% to $343.5 million in 2023, then climbed by 10.03% to $377.9 million in 2024, then surged by 30.59% to $493.5 million in 2025, then fell by 6.54% to $461.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $461.3 million in Q1 2026, $493.5 million in Q4 2025, and $439.8 million in Q3 2025.